Výsledky vyhledávání

Long-term outcomes of imatinib treatment for chronic myeloid leukemia

Autor: Andreas, Hochhaus, Richard A, Larson, François, Guilhot, Jerald P, Radich, Susan, Branford, Timothy P, Hughes, Michele, Baccarani, Michael W, Deininger, Francisco, Cervantes, Satoko, Fujihara, Christine-Elke, Ortmann, Hans D, Menssen, Hagop, Kantarjian, Stephen G, O'Brien, Brian J, Druker, G, Verhoef

Publikováno v: New England Journal of Medicine, 376(10), 917-927. Massachussetts Medical Society
Recercat. Dipósit de la Recerca de Catalunya
instname
Hochhaus, A, Larson, R A, Guilhot, F, Radich, J P, Branford, S, Hughes, T P, Baccarani, M, Deininger, M W, Cervantes, F, Fujihara, S, Ortmann, C-E, Menssen, H D, Kantarjian, H, O'Brien, S G, Druker, B J & IRIS Investigators 2017, ' Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia ', New England Journal of Medicine, vol. 376, no. 10, pp. 917-927 . https://doi.org/10.1056/NEJMoa1609324
Dipòsit Digital de la UB
Universidad de Barcelona

BACKGROUND Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses on the basis of more than 10 years of follow-up in patients with CML who we

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe5f9d9480c53312f3173ef07dd1cbc5
https://hdl.handle.net/11541.2/125989

Zobrazit plný text záznamu

Akademický článek

Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials.

Autor: Zouboulis CC; European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.; Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany., Kyrgidis A; European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.; Department of Maxillofacial Surgery, Papanikolaou General Hospital of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece., Alavi A; European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.; Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA., Jemec GBE; European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.; Department of Dermatology, Zeeland University Hospital, Roskilde, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Martorell A; European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.; Department of Dermatology, Hospital de Manises, Valencia, Spain., Marzano AV; European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.; Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.; Department of Pathophysiology and Transplantation, Università Degli Studi di Milano, Milan, Italy., van der Zee HH; European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.; Department of Dermatology, Erasmus Medical Center, Rotterdam, The Netherlands., Wozniak MB; Novartis Ireland Limited, Dublin, Ireland., Martinez AL; Novartis Pharma AG, Basel, Switzerland., Kasparek T; Novartis Pharma AG, Basel, Switzerland., Bachhuber T; Novartis Pharma AG, Basel, Switzerland., Ortmann CE; Novartis Pharma AG, Basel, Switzerland., Lobach I; Novartis Ireland Limited, Dublin, Ireland., Thomas N; Novartis Pharma AG, Basel, Switzerland., Ravichandran S; Novartis Pharmaceuticals, East Hanover, New Jersey, USA., Tzellos T; European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.; Department of Dermatology, Nordland Hospital Trust, Bodø, Norway.

Publikováno v: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2024 Oct 19. Date of Electronic Publication: 2024 Oct 19.

Zobrazit plný text záznamu

Report

International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: A post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab.

Autor: Zouboulis CC; European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.; Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany., Prens EP; European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.; Department of Dermatology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands., Sayed CJ; European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.; Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Molina-Leyva A; European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.; Hidradenitis Suppurativa Unit, Instituto de Investigación Biosanitaria ibs and Servicio de Dermatologia, Hospital Universitario Virgen de Las Nieves, Granada, Spain., Bettoli V; European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.; Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, Italy., Romanelli M; European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.; Department of Dermatology, University of Pisa, Pisa, Italy., Szepietowski JC; European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.; Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wrocław, Poland., Martinez AL; Novartis Pharma AG, Basel, Switzerland., Kasparek T; Novartis Pharma AG, Basel, Switzerland., Lobach I; Novartis Pharma AG, Basel, Switzerland., Wozniak MB; Novartis Ireland Limited, Dublin, Ireland., Ortmann CE; Novartis Pharma AG, Basel, Switzerland., Thomas N; Novartis Pharma AG, Basel, Switzerland., Bachhuber T; Novartis Pharma AG, Basel, Switzerland., Ravichandran S; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA., Tzellos T; European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.; Department of Dermatology, Nordland Hospital Trust, Bodø, Norway.

Publikováno v: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2024 Jun; Vol. 38 (6), pp. e496-e499. Date of Electronic Publication: 2023 Dec 06.

Zobrazit plný text záznamu

Akademický článek

Secukinumab versus guselkumab in the complete resolution of ustekinumab-resistant psoriatic plaques: The ARROW study.

Autor: Krueger J; Laboratory of Investigative Dermatology, The Rockefeller University, New York, New York, USA., Langley RG; Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada., Nigen S; Sima Recherche, Université de Montréal, Montreal, Quebec, Canada., Kasparek T; Novartis Pharma AG, Basel, Switzerland., Di Comite G; Novartis Pharma K.K., Tokyo, Japan., Ortmann CE; Novartis Pharma AG, Basel, Switzerland., Garcet S; Laboratory of Investigative Dermatology, The Rockefeller University, New York, New York, USA., Kolbinger F; Novartis Institutes for BioMedical Research, Basel, Switzerland., Reich K; Translational Research in Inflammatory Skin Disease, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Publikováno v: Experimental dermatology [Exp Dermatol] 2023 Oct; Vol. 32 (10), pp. 1834-1847. Date of Electronic Publication: 2023 Jun 05.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Vyhledávací nástroje:

Upřesnit hledání